cannabidivarin/cannabigerolic acid (CNBX RCC-33) / CNBX Pharma - LARVOL DELTA

CNBX Files New PCT Patent Application For Cannabinoids-Based Neoadjuvant Cancer Therapy (PRNewswire) - "CNBX Pharmaceuticals Inc...announced today that the Company has filed a new patent application titled 'COMPOSITIONS COMPRISING CANNABINOIDS AND METHODS OF USE THEREOF IN THE TREATMENT OF CANCER' under the Patent Cooperation Treaty...Said patent application relates to several of the drug candidates currently under development by the Company for the treatment of various types of cancer, including Colorectal Cancer, Breast Cancer and Melanoma, and specifically to the usage of said drug candidates as a new form of Neoadjuvant Cancer Therapy....The company is actively pursuing the development of its core drug candidate CNBX RCC-33, under the guidance of Dr. Sigalit Arieli Portnoy, the Company's Regulatory Affairs specialist, and in preparation of a pre-IND meeting with the FDA and with plans for conducting a First In-Human Phase l/ll(a) clinical validation study."

New P1/2 trial • Patent • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Melanoma • Oncology • Solid Tumor

CNBX Patent Application “Composition and Method for Treating Cancer with Cannabinoids“ Enters National Phase in US and Israel (PRNewswire) - "CNBX Pharmaceuticals Inc...announced today that the Company's patent application titled 'COMPOSITION AND METHOD FOR TREATING CANCER WITH CANNABINOIDS' was filed on October 12, 2022 with the US Patent and Trademark Office (USPTO) and with the Israel Patent Office under a national phase of International Patent Application. National phase filing in Europe will follow....Said patent application relates to several of the drug candidates on the Company's pipeline for the treatment of various types of cancer, including CNBX RCC-33, for the treatment of colorectal cancer currently being developed and prepared for a pre-IND meeting with the FDA and a first-in-human Phase I/II(a) validation study."

Patent • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

CNBX Pharmaceuticals Granted Patent in Hong Kong (PRNewswire) - "CNBX Pharmaceuticals Inc...announced that it has received a Grant of Patent notice by the Patent Registry, Intellectual Property Department, The Government of the Hong Kong Special Administrative Region. Said notice relates to the Company's patent titled: System and Method for High Throughput Screening of Cancer Cells....This process has already been instrumental for the Company in producing several promising cancer treatment drug candidates, which are now at various stages of the regulatory pathway, including its novel drug candidate RCC-33 for the treatment of colorectal cancer."

Patent • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

CNBX Selects API Supplier Purisys to Support Planned IND Fillings and Phase I/II (a) Clinical Trials (PRNewswire) - "Cannabics Pharmaceuticals Inc...announced today that it has signed an agreement with Purisys...for supply of Good Manufacturing Practice (GMP) grade APIs required for the manufacturing of RCC-33, the company's colorectal cancer treatment drug candidate. Under said agreement, Purisys will also support CNBX throughout an IND filing process, including providing all necessary and related information concerning Chemistry Manufacturing and Controls (CMC) in the form of a comprehensive technical package to be presented to the FDA. APIs supplied under said agreement will be used by Company in Phase I/II (a) clinical studies that it is planning to launch in 2022."

Licensing / partnership • New P1/2 trial • Colorectal Cancer • Gastrointestinal Cancer • Oncology

Meet CNBX at Radiation Therapy Conference (RTC) 2021 in Chicago (PRNewswire) - "Cannabics Pharmaceuticals Inc...announced today that Company Scientific Advisory Board Member, Dr. Yonina Tova (MD), an internationally recognized Radiation Oncologist, will be attending the American Society of Radiologic Technologists (ASRT) Radiation Therapy Conference (RTC) in Chicago on October 26, 2021...Company Director and Head of Advisory Board, Dr. Gil Feiler, commented: '....Our colorectal cancer treatment drug candidate RCC-33 could potentially improve the standard of care for neoadjuvant treatment by incorporating our cannabinoid-based neoadjuvant treatment into the standard of care.'"

Clinical • Colorectal Cancer • Gastrointestinal Cancer • Oncology

Combination of UV and MS/MS detection for the LC analysis of cannabidiol-rich products. (PubMed, Talanta) - "Here, we present a high-throughput approach based on liquid chromatography coupled to UV and tandem mass spectrometric detection for the determination of CBD, THC, and six other minor cannabinoids (cannabigerolic acid, cannabidivarin, cannabinol, cannabigerol, cannabidiolic acid, and tetrahydrocannabinolic acid) in a wide range of concentrations and in a variety of matrices, including oils, hydrophobic ointments, water-soluble liquids, plant material and gelatinous gummies...CBD was analyzed in the range of 0.5-60,000 μg/g in gummies, 1-120,000 μg/g in oils, ointments and liquids, and 5-300,000 μg/g in plant material. The developed method was used for the analysis of thirteen real products with a wide range of CBD content, with positive THC findings in twelve of them."

Journal • Mood Disorders • Pain • Psychiatry

Cannabics Pharmaceuticals' Drug Candidate Exhibits 30% Tumor Volume Reduction in Mice (PRNewswire) - "Cannabics Pharmaceuticals Inc...released...the interim results of its second in-vivo POC study evaluating the efficacy of company's proprietary drug candidate RCC-33 for the treatment of colorectal cancer on mice....Interim study results confirmed the potential efficacy of RCC-33 as a systemic treatment for colorectal cancer when administered orally, showing a 30% reduction in tumor volume in comparison with sham control mice, after 24 days of treatment. The results indicated statistical significance with a p-value less than 0.05."

Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Oncology

Cannabics Pharmaceuticals Launches a New Research Program to develop a Melanoma Treatment Drug Candidate for FDA Approval Track (PRNewswire) - “Cannabics Pharmaceuticals…announced today the launching of a new research program for the development of a Melanoma antitumor targeting medicine. The announcement comes amidst the recent completion of a series of preclinical experiments within the company's in-house research facilities demonstrating promising antitumor results on Melanoma cell lines. The launching of the new research program for the development of Melanoma treatment follows a previous development by the company of Cannabics® RCC-33, a proprietary formula for the treatment of Colorectal Cancer, who demonstrated a 33% reduction in tumor volume and a 35% increase in survival rate in recent in-vivo experiments in mice.”

Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Melanoma • Oncology • Skin Cancer • Solid Tumor

Cannabics Pharmaceuticals to Initiate in-vivo Dose Response Study on Proprietary Colorectal Cancer Drug Candidate RCC-33 (PRNewswire) - "Cannabics Pharmaceuticals Inc...announced...it is initiating a Dose Response in-vivo Study in mice; results to be included as part of the Product Package to be submitted to the U.S. Food and Drug Administration along with a Pre-IND meeting request....The Dose Response Study comes in light of previously reported results indicating a 33% reduction in tumor volume and a 35% prolonged survival rate in mice inoculated with human colorectal cancer cells and exposed to Cannabics™ RCC-33."

Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Oncology

Cannabics Pharmaceuticals' Drug Candidate RCC-33 Prolongs Survival Rate in Mice Inoculated with Human Colorectal Cancer Cells (PRNewswire) - "Cannabics Pharmaceuticals Inc...released today the concluding results of its in-vivo study evaluating the efficacy of the company's proprietary drug candidate RCC-33 in prolonging survival rate in mice inoculated with human colorectal cancer cells. Study results indicate a 35% prolonged survival rate in mice exposed to RCC-33 in comparison with sham control mice....Company is aiming to schedule a pre-IND meeting with the US Food and Drug Administration by next quarter and start Phase 1/2a trials by beginning of 2022."

Clinical • New P1/2 trial • Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Oncology

Cannabics Pharmaceutical's Interim in-vivo Study Results Show a 27% Lower Tumor Volume in Mice Treated with Company's Proprietary Drug Candidate for Colorectal Cancer (PRNewswire) - "Cannabics Pharmaceuticals Inc...announced...that it has obtained interim results for its ongoing in-vivo study evaluating the efficacy of the company's proprietary drug candidate RCC-33 for colorectal cancer in nude-mice. The interim results show a 27% reduction in tumor volume in mice exposed to RCC-33 in comparison with sham control mice. Both groups were inoculated with colorectal cancer cells. Daily doses of intraperitoneal (IP) delivery of RCC-33 or sham were initiated on day 5. Differences in tumor volume between the two groups were first observed after 5 days of treatment (day 10)."

Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Oncology

Cannabics Concludes a Pre-Clinical Study on Human Biopsies in Preparation for FDA pre-IND Meeting Request on Colorectal Cancer Drug Candidate RCC-33 (PRNewswire) - "The results show an antitumor synergistic effect of the active compounds, thus confirming the company' previously obtained data on the antitumor properties of the drug candidate when screened on colorectal cell lines....'Our next step will be launching a study on mice to try and demonstrate the same synergistic effect and see tumor growth attenuation in-vivo'"

Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Oncology

Cannabics Pharmaceuticals Prepares to Submit the FDA with a pre-IND Meeting Request for its Proprietary Colon Cancer Drug Candidate, CANNABICS RCC-33 (PRNewswire) - "Cannabics Pharmaceuticals Inc...announced...that it has signed an agreement with a leading clinical quality and validation processes consultancy to oversee the preparation and submission of a Pre-IND Meeting request to the FDA on its anti-tumor Drug Candidate CANNABICS™ RCC-33, the world's first cannabinoid-based antitumor Drug Candidate for the treatment of Colorectal Cancer. The pre-IND Meeting request with the FDA is expected to be submitted during Q1 of 2021, and subsequently take place in the first half of 2021."

Clinical • Licensing / partnership • Colorectal Cancer • Gastrointestinal Cancer • Oncology